Skip to main content
OpenTrials
Completed

NCT Number: NCT03494387

VitamIn and oXygen Interventions and Cardiovascular Events

This study examines the risks and benefits of antioxidants and normal versus high inspiratory oxygen fraction during anaesthesia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Abdominalcentret, Rigshospitalet, Copenhagen, Denmark

Loading trial locations.

About this study

Adult patients with risk factors for developing postoperative cardiac complications will be enrolled in the study. The patients will be randomised to receiving antioxidants or placebo perioperatively and 30% or 80% inspiratory oxygen concentration during anaesthesia and 2 hours postoperatively. The primary outcome is MINS (myocardial injury after non-cardiac surgery). The antioxidants are ascorbic acid (vitamin C) 3 grams intravenously preoperatively and N-acetylcysteine 100 milligrams/kilogram body weight intravenous infusion for 4 hours, starting at the same time as anaesthesia.

The study is a long-term follow-up study of the risk of mortality, MI and readmissions performed at 1 year after inclusion of the last patient. Two other follow-up studies are planned: One investigation of ischaemic troponin elevations defined as peak troponin levels above the internationally defined thresholds without extracardiac causes; another investigating the intervention effects in the subgroup of patients undergoing vascular surgery with specific emphasis on episodes of intraoperative hypotension within the following thresholds: MAP below 70 mmHg, 65 mmHg, 60 mmHg and 55 mmHg.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All of the listed criteria (1.-4.) must be met.

  • Age 45 years or above
  • Elective or acute surgery in general anaesthesia
  • Scheduled for abdominal, orthopaedic, or vascular surgery with expected surgery duration of one hour or more.
  • Fulfil any 1 of the following 5 criteria:
  • - History of coronary artery disease including angina
  • - History of stroke
  • - Undergoing vascular surgery
  • - History of peripheral arterial disease
  • - Any 2 of the following 8 criteria: i. Acute surgery ii. Current or previous daily smoking iii. History of hypertension iv. Diabetes mellitus requiring medical treatment v. History of transient cerebral ischemia vi. Plasma creatinine >175 µM vii. Age 70 years or above viii. History of congestive heart failure

Exclusion criteria

  • Surgery within 30 days prior to operation
  • Arterial oxygen saturation below 90% without oxygen supplementation
  • Inability to give informed consent
  • Drug allergy towards any of the drugs involved in the trial
  • Previous treatment with bleomycin
  • Pregnancy

Treatment and study plan

Oxygen

Drug

80% versus 30% inspiratory oxygen concentration

Antioxidants

Drug

Antioxidants versus placebo

Other names: Ascorbic acid, N-acetylcysteine

Primary outcomes

  1. Myocardial injury after non-cardiac surgery (MINS)

    Time frame: 30 days

    Troponin measurement the first 3 postoperative days. Assessed by area under the curve.

Secondary outcomes

  1. Mortality

    Time frame: During the study period until completion of last visit of last patient

    Assessed as time to event analysis

  2. Non-fatal myocardial infarction

    Time frame: During the study period until completion of last visit of last patient

    Assessed as time to event analysis

  3. Non-fatal Serious Adverse Event

    Time frame: During the study period until completion of last visit of last patient

    Assessed as time to event analysis

Other outcomes

  1. Surgical site infection

    Time frame: Assessed at postoperative day 30

    Infection in surgical area as defined by the Center for Disease Control

  2. Pneumonia

    Time frame: Assessed at postoperative day 30

    Pneumonia as defined by the Center for Disease Control

  3. Sepsis

    Time frame: Assessed at postoperative day 30

    Sepsis as defined by the joint task force by the European Society of Intensive Care Medicine and the Society of Critical Care Medicine

  4. Acute respiratory failure

    Time frame: Assessed at postoperative day 30

    Acute respiratory failure defined as the need for controlled ventilation or oxygen saturation of 900% or less despite of oxygen therapy

  5. Acute kidney injury

    Time frame: Assessed at postoperative day 30

    Acute kidney injury as defined Kidney Disease Improving Global Outcomes guidelines

Sponsors and collaborators

Lead sponsor

University Hospital Bispebjerg and Frederiksberg

Other

Registry information

Official study title

Hyperoxia and Antioxidants During Major Non-cardiac Surgery and Risk of Cardiovascular Complications, a Blinded 2x2 Factorial Randomised Clinical Trial

Acronym: VIXIE

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Apr 11, 2018
Registry last updated
Apr 30, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.